ALXO — ALX Oncology Holdings Share News
0.000.00%
Last trade - 00:00Brief: ALX Oncology And Quantum Leap Healthcare Collaborative Announce Selection Of Evorpacept In I-Spy-P1 Trial In Combination With Enhertu In Breast Cancer
Brief: Alx Oncology Announces First Patient Dosed In Phase 2 Investigator-Sponsored Trial Of Evorpacept
ALX Oncology Holdings Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP- Avalara, Global Blood Therapeutics, Tyson Foods
Brief: ALX Oncology Reports Second Quarter 2022 Results
ALX Oncology Holdings Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: ALX Oncology’S Evorpacept Receives Fast Track Designation As First-Line Treatment For Head And Neck Squamous Cell Carcinoma
Brief: Alx Oncology Receives U.S. FDA Orphan Drug Designation For Evorpacept For The Treatment Of Patients With Acute Myeloid Leukemia
Brief: Alx Oncology Announces Evorpacept Clinical Program Updates
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM
Brief: ALX Oncology Holdings Q1 GAAP Loss Per Share $0.60
Brief: Alx Oncology Holdings Board Increases Size Of Its Board Of Directors From Six To Seven
Brief: Alx Oncology Holdings Inc Files For Mixed Shelf Of Upto $450 Mln
Brief: Alx Oncology Announces First Patient Dosed In Aspen-06
U.S. RESEARCH ROUNDUP-Alx Oncology Holdings, First Horizon, Intricon
Brief: ALX Oncology Reports Fourth Quarter And Full Year 2021 Financial Results
U.S. RESEARCH ROUNDUP-CVS Health, Shopify, WEX
Brief: Alx Oncology Receives U.S. FDA Orphan Drug Designation For Gastric And Gastroesophageal Junction Cancer Treatment
Brief: ALX Oncology Provides Corporate Update And Highlights Key Milestones In 2022